How we made the decision

We check our guidelines regularly to ensure they remain up to date. We based the decision on surveillance 4 years after the publication of NICE's guideline on hyperphosphataemia in chronic kidney disease (CG157) in 2013, 4 years after the publication of NICE's guideline on chronic kidney disease in adults (CG182) in 2014 and 2 years after the publication of NICE's guideline on chronic kidney disease: managing anaemia (NG8) in 2015.

For details of the process and update decisions that are available, see ensuring that published guidelines are current and accurate in developing NICE guidelines: the manual.

The previous surveillance update decision for the guideline on hyperphosphataemia in chronic kidney disease is on our website. No previous surveillance was performed for the guidelines on chronic kidney disease in adults or chronic kidney disease: managing anaemia.

New evidence

We found 13 studies in a search for systematic reviews and randomised controlled trials published between 25 November 2013 and 2 September 2016. We also considered 2 additional studies identified by members of the guideline committee who originally worked on this guideline.

We also considered evidence identified in previous surveillance 2 years after publication of the guideline. This included 8 studies identified by search.

From all sources, we considered 23 studies to be relevant to the guideline.

We also checked for relevant ongoing research, which will be evaluated again at the next surveillance review of the guideline.

See appendix A1: summary of evidence from surveillance for details of all evidence considered, and references.

Chronic kidney disease in adults

We found 104 studies in a search for systematic reviews and randomised controlled trials published between 25 November 2013 and 2 September 2016. We also considered 1 additional study identified by members of the guideline committee who originally worked on this guideline.

From all sources, we considered 105 studies to be relevant to the guideline.

We also checked for relevant ongoing research, which will be evaluated again at the next surveillance review of the guideline.

See appendix A2: summary of evidence from surveillance for details of all evidence considered, and references.

We found 32 studies in a search for systematic reviews and randomised controlled trials published between 14 August 2014 and 2 September 2016. We also considered 2 additional studies identified by members of the guideline committee who originally worked on this guideline.

From all sources, we considered 34 studies to be relevant to the guideline.

We also checked for relevant ongoing research, which will be evaluated again at the next surveillance review of the guideline.

See appendix A3: summary of evidence from surveillance for details of all evidence considered, and references.

Views of topic experts

We considered the views of topic experts, including those who helped to develop the guideline.

Views of stakeholders

Stakeholders are consulted only if we decide not to update the guideline following checks at 4 and 8 years after publication. Because 4-year surveillance reviews were performed, and the decision was to update all the guidelines, we did not consult on the decision.

See ensuring that published guidelines are current and accurate in developing NICE guidelines: the manual for more details on our consultation processes.

NICE Surveillance programme project team

Sarah Willett / Kay Nolan (from February 2017)
Associate Director

Philip Alderson
Consultant Clinical Adviser

Emma McFarlane
Technical Adviser

Stephen Sharp
Technical Analyst

The NICE project team would like to thank the topic experts who participated in the surveillance process.

ISBN: 978-1-4731-2482-0


This page was last updated: 24 April 2017